Inflammation & Regeneration Sample Clauses

Inflammation & Regeneration. Timing Major Milestones with respect to expected results, achievements, deliverables Start of Program • Determine short and long-term goals Year 1 • Imaging NF-κB dependent luciferase activation in transgenic autoimmune model • Validation of fluorescent macrophage ligand (PK 11195) in cell cultures • Imaging of cathepsin B and H, and apoptosis (Annexin 5) in inflammation models • Cross-breed NF-kB luciferase mice into mouse strain with spontaneous development of arthritis for imaging of NF-kB activity • Construction of plasmids allowing multimodal imaging of NF-kB activity-preliminary testing in cell cultures • Improved techniques for labelling neural progenitor and stem cells • Multi-modality tracking of stem cells based on various marker genes • Annual implementation plan for Year 2 Year 2 • Publication: NF-kB activation in autoimmune disease model • Imaging NF-κB activation in model of arthritis-assessment of NF-kB dynamics • Employ fluorescent macrophage ligand (PK 11195) in mouse models of inflammation • Effect of specific NF-kB inhibitors on optical and clinical markers of disease • Development of utility of probes for optical imaging of complement activation and ROS detection • Targeted probes against (α β integrins)-validation in cell cultures • Experimental studies of constructs for multimodal imaging of NF-kB activation in cell culture studies • Production of transgenic reporter mice allowing multimodal imaging of NF-κB activation • Targeted probes against (α β integrins)-validation in cell cultures • Develop transgenic reporter mice for in vivo imaging of specific protein kinase activity- proof of principle • Development of DNA constructs allowing imaging of various protein kinases • Multi-modal imaging and trafficking of NP/NCS in various models (stroke, PD) • Controlled expression of marker and therapeutic genes in transplanted stem cells in animal models • Validation of image-based functional assessment of novel stem cell therapies • Annual implementation plan for Year 3 Year 3 • Publication: NF-kB activation in autoimmune disease model combined with optical imaging probes and effect of NF-kB inhibitors • Publication of in vivo imaging of protein kinase activity- validation study (proof of principle) • Development of Cre-dependent expression of luciferase regulated by NF-kB for tissue specific assessment of NF-kB activity • Optical imaging probes against ROS and complement activation used in mouse models after successful validation in in vitr...
AutoNDA by SimpleDocs

Related to Inflammation & Regeneration

  • Influenza Vaccination The parties agree that influenza vaccinations may be beneficial for patients and employees. Upon a recommendation pertaining to a facility or a specifically designated area(s) thereof from the Medical Officer of Health or in compliance with applicable provincial legislation, the following rules will apply:

  • Rhytidectomy Scar revision, regardless of symptoms. • Sclerotherapy for spider veins. • Skin tag removal. • Subcutaneous injection of filling material. • Suction assisted Lipectomy. • Tattooing or tattoo removal except tattooing of the nipple/areola related to a mastectomy. • Treatment of vitiligo. • Standby services of an assistant surgeon or anesthesiologist. • Orthodontic services related to orthognathic surgery. • Cosmetic procedures when performed primarily: o to refine or reshape body structures or dental structures that are not functionally impaired; o to improve appearance or self-esteem; or o for other psychological, psychiatric or emotional reasons. • Drugs, biological products, hospital charges, pathology, radiology fees and charges for surgeons, assistant surgeons, attending physicians and any other incidental services, which are related to cosmetic surgery.

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Infrastructure Vulnerability Scanning Supplier will scan its internal environments (e.g., servers, network devices, etc.) related to Deliverables monthly and external environments related to Deliverables weekly. Supplier will have a defined process to address any findings but will ensure that any high-risk vulnerabilities are addressed within 30 days.

  • Screening 3.13.1 Refuse containers located outside the building shall be fully screened from adjacent properties and from streets by means of opaque fencing or masonry walls with suitable landscaping.

  • Speech Therapy This plan covers speech therapy services when provided by a qualified licensed provider and part of a formal treatment plan for: • loss of speech or communication function; or • impairment as a result of an acute illness or injury, or an acute exacerbation of a chronic disease. Speech therapy services must relate to: • performing basic functional communication; or • assessing or treating swallowing dysfunction. See Autism Services when speech therapy services are rendered as part of the treatment of autism spectrum disorder. The amount you pay and any benefit limit will be the same whether the services are provided for habilitative or rehabilitative purposes.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!